Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7039926,systemic bioavailability,"Following oral administration it is rapidly absorbed from the gastrointestinal tract, its systemic bioavailability being dose-dependent and ranging from 70 to 90%.",Clinical pharmacokinetics of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),%,70 to 90,56310,DB00782,Propantheline
,7039926,volume of distribution,It distributes rapidly and evenly throughout most tissues and fluids and has a volume of distribution of approximately 0.9L/kg.,Clinical pharmacokinetics of paracetamol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[l] / [kg],0.9,56311,DB00782,Propantheline
,7039926,plasma half-life,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),h,1.9 to 2.5,56312,DB00782,Propantheline
,7039926,total body clearance,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[ml] / [kg·min],4.5 to 5.5,56313,DB00782,Propantheline
,7236872,time of peaking (tmax),Propantheline prolonged the absorption phase of atenolol and the time of peaking (tmax) was shifted from 2.1 to 4.5 h.,"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7236872/),h,2.1,56406,DB00782,Propantheline
,7236872,time of peaking (tmax),Propantheline prolonged the absorption phase of atenolol and the time of peaking (tmax) was shifted from 2.1 to 4.5 h.,"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7236872/),h,4.5,56407,DB00782,Propantheline
,3986303,Tmax,"PPB also increased Tmax from 2-8 h (p less than 0.001), and appeared to produce first order absorption of CGZ.",Bioavailability studies with ciglitazone in beagles. Effect of propantheline bromide and metoclopramide HCL on bioavailability of a tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986303/),h,2-8,56779,DB00782,Propantheline
,7389749,peak plasma concentrations,Mean peak plasma concentrations were 20.6 and 53.1 ng/ml after 30 mg and 60 mg respectively.,Plasma levels and urinary excretion of orally administered propantheline bromide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389749/),[ng] / [ml],20.6,67578,DB00782,Propantheline
,7389749,peak plasma concentrations,Mean peak plasma concentrations were 20.6 and 53.1 ng/ml after 30 mg and 60 mg respectively.,Plasma levels and urinary excretion of orally administered propantheline bromide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389749/),[ng] / [ml],53.1,67579,DB00782,Propantheline
,7389749,apparent absorption,"The mean apparent absorption and elimination half-lives after 30 mg dose were 0.22 and 1.57 h respectively, and similar half-lives were found at the higher dose level.",Plasma levels and urinary excretion of orally administered propantheline bromide in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389749/),h,0.22,67580,DB00782,Propantheline
,7389749,elimination half-lives,"The mean apparent absorption and elimination half-lives after 30 mg dose were 0.22 and 1.57 h respectively, and similar half-lives were found at the higher dose level.",Plasma levels and urinary excretion of orally administered propantheline bromide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389749/),h,1.57,67581,DB00782,Propantheline
>,18715548,Absolute bioavailability,"Absolute bioavailability of meloxicam, based on 0-48h measurement, was >0.68 regardless of the type of formulation and treatment.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),,0.68,86774,DB00782,Propantheline
,18715548,AUC(0-24),"Vagal suppression, however, significantly reduced AUC(0-24) (microg h mL(-1)) for Brand (control, 58.8+/-22.0 vs treated, 22.1+/-9.7) but not for FD (control, 63.5+/-17.9 vs treated, 64.6+/-8.9) indicating a reduced absorption rate for the former.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),[h·μg] / [ml],58.8,86775,DB00782,Propantheline
,18715548,AUC(0-24),"Vagal suppression, however, significantly reduced AUC(0-24) (microg h mL(-1)) for Brand (control, 58.8+/-22.0 vs treated, 22.1+/-9.7) but not for FD (control, 63.5+/-17.9 vs treated, 64.6+/-8.9) indicating a reduced absorption rate for the former.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),[h·μg] / [ml],22.1,86776,DB00782,Propantheline
,18715548,AUC(0-24),"Vagal suppression, however, significantly reduced AUC(0-24) (microg h mL(-1)) for Brand (control, 58.8+/-22.0 vs treated, 22.1+/-9.7) but not for FD (control, 63.5+/-17.9 vs treated, 64.6+/-8.9) indicating a reduced absorption rate for the former.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),[h·μg] / [ml],63.5,86777,DB00782,Propantheline
,18715548,AUC(0-24),"Vagal suppression, however, significantly reduced AUC(0-24) (microg h mL(-1)) for Brand (control, 58.8+/-22.0 vs treated, 22.1+/-9.7) but not for FD (control, 63.5+/-17.9 vs treated, 64.6+/-8.9) indicating a reduced absorption rate for the former.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),[h·μg] / [ml],64.6,86778,DB00782,Propantheline
,2277865,half-lives,"Kinetic interpretation of the terminal linear phase of the urinary excretion rate vs. time data yielded mean (+/- SD) half-lives of 4.35 +/- 2.1 hr for NF and 3.42 +/- 0.86 hr for P, which were significantly greater than the mean 1.58 +/- 0.63 hr half-life observed for F.",Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,4.35,100200,DB00782,Propantheline
,2277865,half-lives,"Kinetic interpretation of the terminal linear phase of the urinary excretion rate vs. time data yielded mean (+/- SD) half-lives of 4.35 +/- 2.1 hr for NF and 3.42 +/- 0.86 hr for P, which were significantly greater than the mean 1.58 +/- 0.63 hr half-life observed for F.",Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,3.42,100201,DB00782,Propantheline
,2277865,half-lives,"Kinetic interpretation of the terminal linear phase of the urinary excretion rate vs. time data yielded mean (+/- SD) half-lives of 4.35 +/- 2.1 hr for NF and 3.42 +/- 0.86 hr for P, which were significantly greater than the mean 1.58 +/- 0.63 hr half-life observed for F.",Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,1.58,100202,DB00782,Propantheline
,2277865,half-life,"Kinetic interpretation of the terminal linear phase of the urinary excretion rate vs. time data yielded mean (+/- SD) half-lives of 4.35 +/- 2.1 hr for NF and 3.42 +/- 0.86 hr for P, which were significantly greater than the mean 1.58 +/- 0.63 hr half-life observed for F.",Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,1.58,100203,DB00782,Propantheline
,2277865,biological half-life,The reported mean biological half-life of AZT after a 10 mg/kg intravenous dose to the same strain of rats is 0.76 +/- 0.35 hr (n = 6).,Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,0.76,100204,DB00782,Propantheline
,2778095,Cmax,The pharmacokinetic parameters of droxicam were: Cmax = 1.03 +/- 0.16 micrograms/mL (mean +/- SD).,The influence of gastric emptying on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[μg] / [ml],1.03,107248,DB00782,Propantheline
,2778095,Tmax,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,11.1,107249,DB00782,Propantheline
,2778095,AUC,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[h·μg] / [ml],115.7,107250,DB00782,Propantheline
,2778095,T 1/2 a,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,2.64,107251,DB00782,Propantheline
,2778095,T 1/2 el,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,73.6,107252,DB00782,Propantheline
,2778095,CL/F,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[ml] / [min],3.06,107253,DB00782,Propantheline
,2778095,MRT,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,111.1,107254,DB00782,Propantheline
,2778095,Tmax,"Following modification of gastric emptying, only Tmax (droxicam + metoclopramide = 25.0 +/- 10.8 hr and droxicam + propantheline = 20.8 +/- 8.8 hr) underwent significant change (P less than 0.05).",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,25.0,107255,DB00782,Propantheline
,2778095,Tmax,"Following modification of gastric emptying, only Tmax (droxicam + metoclopramide = 25.0 +/- 10.8 hr and droxicam + propantheline = 20.8 +/- 8.8 hr) underwent significant change (P less than 0.05).",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,20.8,107256,DB00782,Propantheline
,19585373,recovery,"The cumulative (14)C-uracil recovery (%) at 168 h was 92.3, 6.3, or 0.5%, from expired gases, urine, and feces, respectively.",Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19585373/),%,92.3,123096,DB00782,Propantheline
,19585373,recovery,"The cumulative (14)C-uracil recovery (%) at 168 h was 92.3, 6.3, or 0.5%, from expired gases, urine, and feces, respectively.",Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19585373/),%,6.3,123097,DB00782,Propantheline
,19585373,recovery,"The cumulative (14)C-uracil recovery (%) at 168 h was 92.3, 6.3, or 0.5%, from expired gases, urine, and feces, respectively.",Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19585373/),%,0.5,123098,DB00782,Propantheline
,726518,elimination half-life,5. A mean elimination half-life of 9.2 h was obtained for the total radioactivity by pharmacokinetic analysis of plasma and urine levels of 14C.,Identification of some urinary metabolites of propantheline bromide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/726518/),h,9.2,137306,DB00782,Propantheline
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],68.4,148763,DB00782,Propantheline
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],74.3,148764,DB00782,Propantheline
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,1.1,148765,DB00782,Propantheline
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,3.5,148766,DB00782,Propantheline
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],78.3,148767,DB00782,Propantheline
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],88.1,148768,DB00782,Propantheline
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,10,171113,DB00782,Propantheline
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,74,171114,DB00782,Propantheline
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,33,171115,DB00782,Propantheline
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,26,171116,DB00782,Propantheline
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,91,171117,DB00782,Propantheline
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,2-3,171118,DB00782,Propantheline
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,3-4,171119,DB00782,Propantheline
,2890459,absolute oral bioavailability,"The absolute oral bioavailability, relative to that after intravenous administration, was 98% +/- 14%.",Absorption studies of the H2-blocker nizatidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890459/),%,98,192484,DB00782,Propantheline
,1487562,maximum peak plasma concentration (Cmax),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),[μg] / [ml],14.0,253528,DB00782,Propantheline
,1487562,time to reach Cmax (tmax),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),h,1.5,253529,DB00782,Propantheline
,1487562,half-life (t1/2),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),h,1.24,253530,DB00782,Propantheline
,1487562,area under the concentration (AUC0-infinity),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),[h·μg] / [ml],47.3,253531,DB00782,Propantheline
,1487562,mean residence time after oral administration (MRTpo),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),h,2.9,253532,DB00782,Propantheline
,1487562,CLR,"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),[ml] / [min],219,253533,DB00782,Propantheline
,1487562,percent cumulative urinary excretion in 0-24 hours,"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),,68.1,253534,DB00782,Propantheline
,4031112,AUCs,"The AUCs for tablets alone, with cholestyramine, and with propantheline were 32.8 +/- 13.3 (+/- SD), 22.4 +/- 12.1, and 40.6 +/- 13.9, respectively, while corresponding values for capsules were 31.7 +/- 9.3, 24.7 +/- 7.9, and 35.9 +/- 12.8.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,32.8,273671,DB00782,Propantheline
,4031112,AUCs,"The AUCs for tablets alone, with cholestyramine, and with propantheline were 32.8 +/- 13.3 (+/- SD), 22.4 +/- 12.1, and 40.6 +/- 13.9, respectively, while corresponding values for capsules were 31.7 +/- 9.3, 24.7 +/- 7.9, and 35.9 +/- 12.8.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,22.4,273672,DB00782,Propantheline
,4031112,AUCs,"The AUCs for tablets alone, with cholestyramine, and with propantheline were 32.8 +/- 13.3 (+/- SD), 22.4 +/- 12.1, and 40.6 +/- 13.9, respectively, while corresponding values for capsules were 31.7 +/- 9.3, 24.7 +/- 7.9, and 35.9 +/- 12.8.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,40.6,273673,DB00782,Propantheline
,4031112,AUCs,"The AUCs for tablets alone, with cholestyramine, and with propantheline were 32.8 +/- 13.3 (+/- SD), 22.4 +/- 12.1, and 40.6 +/- 13.9, respectively, while corresponding values for capsules were 31.7 +/- 9.3, 24.7 +/- 7.9, and 35.9 +/- 12.8.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,31.7,273674,DB00782,Propantheline
,4031112,AUCs,"The AUCs for tablets alone, with cholestyramine, and with propantheline were 32.8 +/- 13.3 (+/- SD), 22.4 +/- 12.1, and 40.6 +/- 13.9, respectively, while corresponding values for capsules were 31.7 +/- 9.3, 24.7 +/- 7.9, and 35.9 +/- 12.8.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,24.7,273675,DB00782,Propantheline
,4031112,AUCs,"The AUCs for tablets alone, with cholestyramine, and with propantheline were 32.8 +/- 13.3 (+/- SD), 22.4 +/- 12.1, and 40.6 +/- 13.9, respectively, while corresponding values for capsules were 31.7 +/- 9.3, 24.7 +/- 7.9, and 35.9 +/- 12.8.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,35.9,273676,DB00782,Propantheline
,4031112,trough concentrations,"The trough concentrations for tablets alone, with cholestyramine, and with propantheline were 0.88 +/- 0.47, 0.61 +/- 0.38, and 1.09 +/- 0.35, respectively; trough concentrations for capsules were 0.77 +/- 0.28, 0.74 +/- 0.28, and 0.96 +/- 0.48, respectively.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,0.88,273677,DB00782,Propantheline
,4031112,trough concentrations,"The trough concentrations for tablets alone, with cholestyramine, and with propantheline were 0.88 +/- 0.47, 0.61 +/- 0.38, and 1.09 +/- 0.35, respectively; trough concentrations for capsules were 0.77 +/- 0.28, 0.74 +/- 0.28, and 0.96 +/- 0.48, respectively.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,0.61,273678,DB00782,Propantheline
,4031112,trough concentrations,"The trough concentrations for tablets alone, with cholestyramine, and with propantheline were 0.88 +/- 0.47, 0.61 +/- 0.38, and 1.09 +/- 0.35, respectively; trough concentrations for capsules were 0.77 +/- 0.28, 0.74 +/- 0.28, and 0.96 +/- 0.48, respectively.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,1.09,273679,DB00782,Propantheline
,4031112,trough concentrations,"The trough concentrations for tablets alone, with cholestyramine, and with propantheline were 0.88 +/- 0.47, 0.61 +/- 0.38, and 1.09 +/- 0.35, respectively; trough concentrations for capsules were 0.77 +/- 0.28, 0.74 +/- 0.28, and 0.96 +/- 0.48, respectively.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,0.77,273680,DB00782,Propantheline
,4031112,trough concentrations,"The trough concentrations for tablets alone, with cholestyramine, and with propantheline were 0.88 +/- 0.47, 0.61 +/- 0.38, and 1.09 +/- 0.35, respectively; trough concentrations for capsules were 0.77 +/- 0.28, 0.74 +/- 0.28, and 0.96 +/- 0.48, respectively.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,0.74,273681,DB00782,Propantheline
,4031112,trough concentrations,"The trough concentrations for tablets alone, with cholestyramine, and with propantheline were 0.88 +/- 0.47, 0.61 +/- 0.38, and 1.09 +/- 0.35, respectively; trough concentrations for capsules were 0.77 +/- 0.28, 0.74 +/- 0.28, and 0.96 +/- 0.48, respectively.",A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4031112/),,0.96,273682,DB00782,Propantheline
